323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Announces Pricing of Underwritten Offering
New Data Demonstrate CD47 Expression Level Helps Predict Response to Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
ALX Oncology Increases Shares Under 2025 Inducement Plan by 1.3 Million
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
SC TO-I
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload
Amended Tender Offer Statement by Issuer